Lineage Cell Therapeutics, Inc. (LCTX)
NYSE American · Healthcare · Biotechnology
$0.9274−0.31%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $235M
- 52-week range
- $0.88 – $2.09
- 52-week change
- −45.61%
- EPS (trailing)
- −$0.19
- Analyst rating
- 1.4 Strong buy
- Next earnings
- Nov 5, 2026
Fiscal year to Dec 2025
- Revenue
- $14.6M (+53.24%)
- Net income
- −$63.5M
- Operating margin
- −251.6%
- Diluted EPS
- −$0.28
- Free cash flow
- −$19.4M
From the company’s annual report on SEC EDGAR.
About Lineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; and OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries. It also offers ReSonance (ANP1), an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of sensorineural hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage.
Headquarters: Carlsbad, United States · 72 employees · lineagecell.com